Abbott Laboratories (ABT) Operating Expenses (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Operating Expenses data on file, last reported at $9.8 billion in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 13.32% year-over-year to $9.8 billion; the trailing twelve-month figure through Mar 2026 stood at $37.4 billion (up 6.3% YoY), and the FY2025 full-year result was $36.3 billion, up 3.27% from the prior year.
• Operating Expenses advanced to $9.8 billion in Q1 2026, from $9.2 billion in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $9.8 billion in Q1 2026 to a low of $8.2 billion in Q1 2023.
• A 5-year average of $8.8 billion and a median of $8.8 billion in 2024 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses slipped 8.29% in 2023 and advanced 13.32% in 2026, its largest moves.
• Tracing ABT's Operating Expenses over 5 years: stood at $8.8 billion in 2022, then declined by 3.71% to $8.5 billion in 2023, then rose by 7.11% to $9.1 billion in 2024, then advanced by 1.6% to $9.2 billion in 2025, then increased by 6.64% to $9.8 billion in 2026.
• Business Quant data shows ABT's Operating Expenses at $9.8 billion in Q1 2026, $9.2 billion in Q4 2025, and $9.3 billion in Q3 2025.